TY - JOUR
T1 - Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland
T2 - Long-term results from the STAMPEDE randomised controlled trial
AU - Parker, Chris C.
AU - James, Nicholas D.
AU - Brawley, Christopher D.
AU - Clarke, Noel W.
AU - Ali, Adnan
AU - Amos, Claire L.
AU - Attard, Gerhardt
AU - Chowdhury, Simon
AU - Cook, Adrian
AU - Cross, William
AU - Dearnaley, David P.
AU - Douis, Hassan
AU - Gilbert, Duncan C.
AU - Gilson, Clare
AU - Gillessen, Silke
AU - Hoyle, Alex
AU - Jones, Rob J.
AU - Langley, Ruth E.
AU - Malik, Zafar I.
AU - Mason, Malcolm D.
AU - Matheson, David
AU - Millman, Robin
AU - Rauchenberger, Mary
AU - Rush, Hannah
AU - Martin Russell, J.
AU - Sweeney, Hannah
AU - Bahl, Amit
AU - Birtle, Alison
AU - Capaldi, Lisa
AU - Din, Omar
AU - Ford, Daniel
AU - Gale, Joanna
AU - Henry, Ann
AU - Hoskin, Peter
AU - Kagzi, Mohammed
AU - Lydon, Anna
AU - OSullivan, Joe M.
AU - Paisey, Sangeeta A.
AU - Parikh, Omi
AU - Pudney, Delia
AU - Ramani, Vijay
AU - Robson, Peter
AU - Srihari, Narayanan Nair
AU - Tanguay, Jacob
AU - Parmar, Mahesh K.B.
AU - Sydes, Matthew R.
N1 - Publisher Copyright:
Copyright: © 2022 Parker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2022/6
Y1 - 2022/6
N2 - Background STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden disease. In this final analysis, we report long-term findings on the primary outcome measure of OS and on the secondary outcome measures of symptomatic local events, RT toxicity events, and quality of life (QoL). Methods and findings Patients were randomised at secondary care sites in the United Kingdom and Switzerland between January 2013 and September 2016, with 1:1 stratified allocation: 1,029 to standard of care (SOC) and 1,032 to SOC+RT. No masking of the treatment allocation was employed. A total of 1,939 had metastatic burden classifiable, with 42% low burden and 58% high burden, balanced by treatment allocation. Intention-to-treat (ITT) analyses used Cox regression and flexible parametric models (FPMs), adjusted for stratification factors age, nodal involvement, the World Health Organization (WHO) performance status, regular aspirin or nonsteroidal anti-inflammatory drug (NSAID) use, and planned docetaxel use. QoL in the first 2 years on trial was assessed using prospectively collected patient responses to QLQ-30 questionnaire. Patients were followed for a median of 61.3 months. Prostate RT improved OS in patients with low, but not high, metastatic burden (respectively: 202 deaths in SOC versus 156 in SOC+RT, hazard ratio (HR) = 064, 95% CI 0.52, 0.79, p < 0.001; 375 SOC versus 386 SOC+RT, HR = 1.11, 95% CI 0.96, 1.28, p = 0164; interaction p < 0.001). No evidence of difference in time to symptomatic local events was found. There was no evidence of difference in Global QoL or QLQ-30 Summary Score. Long-term urinary toxicity of grade 3 or worse was reported for 10 SOC and 10 SOC+RT; long-term bowel toxicity of grade 3 or worse was reported for 15 and 11, respectively. Conclusions Prostate RT improves OS, without detriment in QoL, in men with low-burden, newly diagnosed, metastatic prostate cancer, indicating that it should be recommended as a SOC. Trial registration ClinicalTrials.gov NCT00268476, ISRCTN.com ISRCTN78818544.
AB - Background STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden disease. In this final analysis, we report long-term findings on the primary outcome measure of OS and on the secondary outcome measures of symptomatic local events, RT toxicity events, and quality of life (QoL). Methods and findings Patients were randomised at secondary care sites in the United Kingdom and Switzerland between January 2013 and September 2016, with 1:1 stratified allocation: 1,029 to standard of care (SOC) and 1,032 to SOC+RT. No masking of the treatment allocation was employed. A total of 1,939 had metastatic burden classifiable, with 42% low burden and 58% high burden, balanced by treatment allocation. Intention-to-treat (ITT) analyses used Cox regression and flexible parametric models (FPMs), adjusted for stratification factors age, nodal involvement, the World Health Organization (WHO) performance status, regular aspirin or nonsteroidal anti-inflammatory drug (NSAID) use, and planned docetaxel use. QoL in the first 2 years on trial was assessed using prospectively collected patient responses to QLQ-30 questionnaire. Patients were followed for a median of 61.3 months. Prostate RT improved OS in patients with low, but not high, metastatic burden (respectively: 202 deaths in SOC versus 156 in SOC+RT, hazard ratio (HR) = 064, 95% CI 0.52, 0.79, p < 0.001; 375 SOC versus 386 SOC+RT, HR = 1.11, 95% CI 0.96, 1.28, p = 0164; interaction p < 0.001). No evidence of difference in time to symptomatic local events was found. There was no evidence of difference in Global QoL or QLQ-30 Summary Score. Long-term urinary toxicity of grade 3 or worse was reported for 10 SOC and 10 SOC+RT; long-term bowel toxicity of grade 3 or worse was reported for 15 and 11, respectively. Conclusions Prostate RT improves OS, without detriment in QoL, in men with low-burden, newly diagnosed, metastatic prostate cancer, indicating that it should be recommended as a SOC. Trial registration ClinicalTrials.gov NCT00268476, ISRCTN.com ISRCTN78818544.
UR - http://www.scopus.com/inward/record.url?scp=85131771397&partnerID=8YFLogxK
U2 - 10.1371/journal.pmed.1003998
DO - 10.1371/journal.pmed.1003998
M3 - Article
C2 - 35671327
AN - SCOPUS:85131771397
SN - 1549-1277
VL - 19
JO - PLoS Medicine
JF - PLoS Medicine
IS - 6
M1 - e1003998
ER -